BTIG Research Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock

Glaukos (NYSE:GKOS) had its target price raised by stock analysts at BTIG Research from $164.00 to $193.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s price target points to a potential upside of 19.16% from the company’s current price.

Several other equities analysts also recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $165.00 price target on shares of Glaukos in a report on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. Citigroup boosted their target price on shares of Glaukos from $162.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Needham & Company LLC restated a “buy” rating and issued a $201.00 target price (up from $150.00) on shares of Glaukos in a research report on Thursday. Finally, William Blair restated an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $164.08.

Glaukos Trading Up 7.0%

Shares of NYSE GKOS opened at $161.97 on Thursday. Glaukos has a 12-month low of $73.16 and a 12-month high of $166.00. The company has a market cap of $9.51 billion, a price-to-earnings ratio of -49.38 and a beta of 0.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The stock’s 50 day simple moving average is $136.63 and its 200 day simple moving average is $124.40.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same period in the prior year, the business earned ($0.24) EPS. The firm’s revenue was up 49.6% on a year-over-year basis. Equities research analysts expect that Glaukos will post -0.57 EPS for the current year.

Insider Activity at Glaukos

In other Glaukos news, Director Leana Wen sold 1,700 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. This trade represents a 7.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction dated Thursday, July 16th. The stock was sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the sale, the chief financial officer owned 43,906 shares in the company, valued at $7,024,960. This trade represents a 18.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,273 shares of company stock valued at $9,082,003 in the last ninety days. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. First Horizon Corp lifted its position in shares of Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Glaukos during the fourth quarter valued at $28,000. Larson Financial Group LLC lifted its holdings in shares of Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in shares of Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 215 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Trending Headlines about Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q2 results exceeded expectations. Glaukos reported record second-quarter revenue of $185.6 million, up approximately 50% year over year and well above the $150.9 million analyst consensus. The company’s loss of $0.14 per share was narrower than the expected $0.21 loss and improved from a $0.24 loss a year earlier. Glaukos Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its 2026 revenue outlook. Glaukos now expects full-year revenue of $680 million to $700 million, compared with the prior consensus estimate of approximately $630 million. The higher outlook signals continued momentum for its ophthalmic pharmaceutical and medical technology products. Glaukos Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Preserflo MicroShunt trial enrollment is complete. Completing enrollment advances development of the glaucoma treatment toward future clinical milestones and potentially expands Glaukos’s product pipeline. Glaukos’ Trial of Preserflo MicroShunt Completes Enrollment
• Neutral Sentiment: UBS initiated coverage with a Neutral rating. UBS assigned a $150 price target, below the latest referenced trading level, suggesting the firm views much of Glaukos’s growth potential as reflected in the valuation. Glaukos Coverage Initiated at UBS Group
• Negative Sentiment: Profitability and cash flow remain concerns. Despite strong sales growth, Glaukos posted an operating loss and remains unprofitable, while operating cash flow was negative in the quarter. The company’s valuation therefore continues to depend heavily on sustained growth and eventual margin improvement.
• Negative Sentiment: Insider selling adds a cautionary signal. CFO Alex Thurman sold 10,000 shares for approximately $1.6 million under a pre-arranged Rule 10b5-1 plan. Broader reported insider activity showed sales without purchases over the past six months, though planned transactions do not necessarily indicate a change in business expectations. Glaukos CFO Insider Sale

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.